Mentoring as a Predominant Factor Affecting Well-Being of Older People

The authors of the paper studied the state of well-being of older people who retired and stop working at the company they have worked for over 20 years. The survey provided some useful insights into the problem with the reference to three samples of 10 older people from each group: 1) older people who retired and keep in touch with the previous organisation; 2) older people who retired and continue working at the company as consultants, supervisors, experts, mentors etc.; 3) older people who retired and work in another enterprise and lost the touch with the previous organisation. Retired people took part in present research by completing a questionnaire survey. A set of data was examined by being compared to reveal the state of older people’s well-being criteria predominance in the various sample groups

Quenched Narrow-Line Laser Cooling of 40Ca to Near the Photon Recoil Limit

We present a cooling method that should be generally applicable to atoms with narrow optical transitions. This technique uses velocity-selective pulses to drive atoms towards a zero-velocity dark state and then quenches the excited state to increase the cooling rate. We demonstrate this technique of quenched narrow-line cooling by reducing the 1-D temperature of a sample of neutral 40Ca atoms. We velocity select and cool with the 1S0(4s2) to 3P1(4s4p) 657 nm intercombination line and quench with the 3P1(4s4p) to 1S0(4s5s) intercombination line at 553 nm, which increases the cooling rate eight-fold. Limited only by available quenching laser power, we have transferred 18 % of the atoms from our initial 2 mK velocity distribution and achieved temperatures as low as 4 microK, corresponding to a vrms of 2.8 cm/s or 2 recoils at 657 nm. This cooling technique, which is closely related to Raman cooling, can be extended to three dimensions.Comment: 5 pages, 4 figures; Submitted to PRA Rapid Communication

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial

Aims The objective of the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) was to determine whether aliskiren, a direct renin inhibitor, would improve post-discharge outcomes in patients with hospitalization for heart failure (HHF) with reduced ejection fraction. Pre-specified subgroup analyses suggested potential heterogeneity in post-discharge outcomes with aliskiren in patients with and without baseline diabetes mellitus (DM). Methods and results ASTRONAUT included 953 patients without DM (aliskiren 489; placebo 464) and 662 patients with DM (aliskiren 319; placebo 343) (as reported by study investigators). Study endpoints included the first occurrence of cardiovascular death or HHF within 6 and 12 months, all-cause death within 6 and 12 months, and change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 1, 6, and 12 months. Data regarding risk of hyperkalaemia, renal impairment, and hypotension, and changes in additional serum biomarkers were collected. The effect of aliskiren on cardiovascular death or HHF within 6 months (primary endpoint) did not significantly differ by baseline DM status (P = 0.08 for interaction), but reached statistical significance at 12 months (non-DM: HR: 0.80, 95% CI: 0.64-0.99; DM: HR: 1.16, 95% CI: 0.91-1.47; P = 0.03 for interaction). Risk of 12-month all-cause death with aliskiren significantly differed by the presence of baseline DM (non-DM: HR: 0.69, 95% CI: 0.50-0.94; DM: HR: 1.64, 95% CI: 1.15-2.33; P < 0.01 for interaction). Among non-diabetics, aliskiren significantly reduced NT-proBNP through 6 months and plasma troponin I and aldosterone through 12 months, as compared to placebo. Among diabetic patients, aliskiren reduced plasma troponin I and aldosterone relative to placebo through 1 month only. There was a trend towards differing risk of post-baseline potassium ≥6 mmol/L with aliskiren by underlying DM status (non-DM: HR: 1.17, 95% CI: 0.71-1.93; DM: HR: 2.39, 95% CI: 1.30-4.42; P = 0.07 for interaction). Conclusion This pre-specified subgroup analysis from the ASTRONAUT trial generates the hypothesis that the addition of aliskiren to standard HHF therapy in non-diabetic patients is generally well-tolerated and improves post-discharge outcomes and biomarker profiles. In contrast, diabetic patients receiving aliskiren appear to have worse post-discharge outcomes. Future prospective investigations are needed to confirm potential benefits of renin inhibition in a large cohort of HHF patients without D